International Pharmaceutical Aerosol Consortium on Regulation & Science
The International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) is an international association that seeks to advance the science, and especially the regulatory science, of orally inhaled and nasal drug products (OINDPs) by collecting and analyzing data, and conducting joint research and development projects. Representing the OINDP industry since 2000, IPAC-RS aims to build consensus and contribute to effective regulations and standards by sharing the results of its research through conferences, technical journals, webinars, and discussions with regulatory bodies.
IPAC-RS Roundtable Webinar Series 2022
In 2021, IPAC-RS launched a new webinar series focusing on drug-device combination products with digital components, and digital-health opportunities and challenges more broadly. Presented by SMEs in the pharmaceutical sciences, this opportunity enabled attendees to learn about the latest research and regulatory trends focused on digital devices. See the IPAC-RS Roundtables webpage for links to presentations and recordings for the 5 webinars held in 2021.
Continuing that practice in 2022, IPAC-RS is hosting a new Roundtable series, supplementing the podium presentations held at the IPAC-RS/RDD Joint session (see below for details).
The upcoming IPAC-RS Roundtable topics include:
Patient Centric Product Design - held on September 22, 2022 (see Roundtables webpage to view the recording)
Supply Chain Considerations
Advanced Data Analytics
Respiratory Drug Delivery and IPAC-RS collaborated again and held a jointly organized session at RDD2022 that addressed Regulatory, Science and Technology Innovations Enabling Novel and Improved OINDP Design, Development and Manufacturing. The podium presentations will be supplemented with subsequent in-depth roundtables (see above for details).
The session moderated by Jennifer Wylie (Merck) and Vijay Sethuraman (Genentech) included:
Patient Centric Design: Paul Upham (Genentech)
Sustainability: Richard Henderson (GlaxoSmithKline)
Regulatory Evolution: Prasad Peri (Teva)
Advanced Data Analytics: Will Ganley (Nanopharm)
News and Events
IPAC-RS is pleased to announce the release of the 2022-2024 IPAC-RS Strategic Plan. IPAC-RS is and will remain the leading technical resource and advocate of the global OINDP industry. We encourage you to view the Plan and we look forward to collaborating with all OINDP industry stakeholders in the new year! We extend a special thanks to the IPAC-RS Board for their leadership in connection with the development of this plan.
Read the IPAC-RS 2021 Year in Review to learn more about IPAC-RS's achievements and the benefits of membership.
The report highlights the impressive work IPAC-RS accomplished in 2021.
IPAC-RS Summary of Global Regulatory Developments 2021
IPAC-RS engages actively in reviewing and commenting on regulatory developments around the world, and works collaboratively with all stakeholders to improve science-based regulations affecting orally inhaled and intranasal pharmaceutical products. IPAC-RS prepared a summary of relevant global regulatory developments in 2021.